Are there any adverse interactions between Imuran (azathioprine) and Camrese Lo (birth control)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

No Clinically Significant Interaction Between Imuran and Camrese Lo

There is no documented adverse interaction between Imuran (azathioprine) and Camrese Lo (levonorgestrel/ethinyl estradiol) birth control, and these medications can be used together safely without dose adjustments.

Evidence Base

The available evidence demonstrates no pharmacokinetic or pharmacodynamic interaction between azathioprine and hormonal contraceptives:

  • Azathioprine does not induce hepatic enzymes that metabolize contraceptive hormones, unlike certain anticonvulsants (phenobarbital, phenytoin, carbamazepine) or rifampicin that increase clearance of oral contraceptive steroids 1, 2.

  • Hormonal contraceptives do not affect azathioprine metabolism, which occurs primarily through thiopurine methyltransferase (TPMT) and xanthine oxidase pathways—mechanisms unrelated to estrogen or progestin metabolism 3.

  • No reports exist in the literature of contraceptive failure or azathioprine toxicity when these medications are combined, despite extensive use of azathioprine in women of reproductive age with autoimmune conditions 3.

Clinical Monitoring Remains Essential

While no interaction exists between these specific medications, standard monitoring for azathioprine therapy must continue:

  • Complete blood count monitoring is mandatory: weekly for the first 4 weeks, then monthly for 1-3 months, then every 2 months thereafter to detect bone marrow suppression 3, 4.

  • Liver function tests should be checked monthly for the first 3 months, then every 2 months 3.

  • TPMT activity testing prior to azathioprine initiation helps identify patients at risk for severe myelosuppression 3, 4.

Important Contraceptive Considerations in Azathioprine Users

Pregnancy planning requires special attention in women taking azathioprine:

  • Azathioprine carries FDA pregnancy category D, indicating potential fetal risk, though human data show no consistent increase in birth defects 3.

  • Preconceptional counseling is advised, with attempts to discontinue immunosuppression if disease activity permits 3.

  • If pregnancy occurs on azathioprine, the medication is often continued when disease control is necessary, as outcomes are generally acceptable with careful monitoring 3.

  • Contraception should be reliable in women with advanced liver disease or cirrhosis, as pregnancy carries increased risks of variceal hemorrhage and hepatic decompensation 3.

Actual Drug Interactions to Avoid with Azathioprine

The clinically significant interactions with azathioprine involve entirely different medications:

  • Allopurinol or febuxostat cause severe, life-threatening myelotoxicity and require 75% azathioprine dose reduction if co-administration is unavoidable 3, 4.

  • Warfarin may require dose adjustment as azathioprine can cause warfarin resistance 3, 4.

  • Other immunosuppressants increase cumulative myelotoxicity risk 4.

  • Cotrimoxazole increases hematologic toxicity risk 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Azathioprine and Pyridostigmine: Side Effects and Monitoring

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.